Pharmaceutical scale-up is not simply a matter of making bigger batches. Consistently maintaining sterility, potency, along with other Critical Quality Attributes (CQAs), as well as stability across every stage of production at large volumes is the goal.

What makes scale-up genuinely difficult is that the physics changes. At small scale, conditions can be tightly controlled with relative ease. As batch sizes grow, mixing becomes less efficient, heat removal becomes more difficult, and equipment behaves differently. The engineering challenges compound quickly. Even small variations in processing conditions (temperature shifts, shear inconsistencies, and even minor changes in solvent removal dynamics) can meaningfully affect CQAs, including drug release profiles and long-term stability.

This guide from the team at Agno Pharmaceuticals explores how to scale up pharmaceutical production effectively and sustainably, with a focus on successful technology transfer for sterile dosage forms.

Scale-Up Strategy & Planning

A successful scale-up begins with designing processes that are inherently scalable and suitable to take into cGMP manufacturing. Instead of focusing solely on laboratory conditions, the scale-up strategy must account for engineering fundamentals and process physics, particularly the interaction between mixing and heat transfer. Also, off-the-shelf equipment is preferred if at all possible.

Key process parameters that must be designed for scalability include:

• Agitation and impeller design: Impeller geometry directly influences mixing uniformity and shear distribution across the batch.
• Shear forces and energy input: The relationship between power input and volume determines whether mixing conditions can be faithfully reproduced at larger scale. Tip speed, a function of impeller diameter and rotational speed, is another critical parameter for maintaining consistent shear.
• Mass and heat transfer efficiency: At larger scales, the surface area-to-volume ratio decreases, reducing heat exchange efficiency and mixing uniformity.
• Thermal gradients and temperature control: As thermal interdependencies increase, maintaining uniform temperature conditions requires active engineering controls.

Maintaining these relationships across scales is what ensures the process behaving as expected.

Strategic planning also includes defining clear milestones: engineering runs, GMP batches, and validation activities with appropriate resource allocation across equipment, personnel, and analytical capabilities. A well-planned development pathway reduces the risk of late-stage surprises and accelerates time to market.

Critical Process Parameters in Scale-Up

Critical Process Parameters (CPPs) are the variables that directly influence product quality and must be carefully controlled during scale-up. Using a Quality by Design (QbD) framework, CPPs are identified early and systematically linked to CQAs. These measurable characteristics define product quality, such as sterility, particle size, and drug release.

• Scaling Principles: CPPs are translated across scales using a combination of geometric similarity (maintaining equipment proportions), dynamic similarity (preserving flow and energy conditions), and formulas (like Reynolds, Nusselt, and Froude which are some of the key dimensionless formulas in fluid mechanics and heat transfer) that describe the underlying physics of the process. The goal is not to replicate exact equipment conditions but to replicate the physical behavior of the process.

• Application by Dosage Form: The specific CPPs that matter most depend heavily on the complexity of the formulation:
  • Simple sterile systems like aqueous injectables primarily require control of mixing kinetics, filtration throughput and pressure, filter surface area, thermal profiles, and filling speed.
  • Complex systems such as PLGA microspheres, nanosuspensions, or emulsion-based formulations introduce additional CPPs including homogenization energy, tip speed, emulsification shear, solvent removal dynamics, and sedimentation behavior during filling.

The outcome of rigorous CPP identification is a defined design space: the envelope of operating conditions within which the process consistently meets quality specifications. This design space, developed through statistically designed experiments (DoE), becomes the foundation for scale-up, tech transfer, and validation. It reduces late-stage failures and gives manufacturing teams a clear, evidence-based target to hit.

Heat Transfer, Mixing Dynamics, & Thermal Operations

Heat transfer and mixing are inseparable during pharmaceutical scale-up. As equipment size increases, the surface area-to-volume ratio decreases, meaning the same vessel geometry that provided efficient heat exchange at pilot scale becomes progressively less effective at commercial scale. Heat removal or input grows slower, mixing becomes less uniform, and temperature gradients become more pronounced.

Mixing plays three critical roles in managing thermal behavior across a batch:

• It distributes heat uniformly to prevent localized overheating or cooling.
• It reduces temperature gradients that could alter reaction kinetics.
• It enhances convective heat transfer by continuously bringing material into contact with temperature-controlled surfaces.

At larger scales, however, each of these functions becomes harder to maintain:

• Turbulence decreases as vessel size grows, limiting the efficiency of heat distribution.
• Dead zones (regions of poor flow) can form within large vessels, creating areas of inconsistent thermal exposure.
• Increased viscosity (which is itself temperature-dependent) can further reduce mixing efficiency, creating a compounding effect.

The consequences of inadequate thermal control at scale are significant. API degradation, particle growth or aggregation in nanosuspension systems, altered release profiles, and compromised product stability can all result from seemingly small temperature excursions. For temperature-sensitive materials like PLGA polymers, the margin for error is narrow.

As a result, implementing proactive mitigation strategies is critical. Managing heat transfer at scale requires a combination of equipment design, process optimization, and active monitoring:

• Optimizing impeller type and agitation speed to maintain adequate turbulence and prevent dead zones
• Enhancing heat exchange through jacketed vessels and internal coils
• Adjusting process time to allow for thermal equilibration at each stage
• Conducting thermal mapping studies and scale-down modeling to predict large-scale behavior before committing to full production runs

At Agno, we apply integrated mixing–thermal modeling during process development to ensure that what is designed at small scale can be reliably reproduced at commercial scale.

Technology Transfer Best Practices

Technology transfer is the process of moving a developed formulation and its associated process knowledge from one site or team to another, most commonly from development to manufacturing. Done well, it is a seamless handoff that preserves everything learned during development. Done poorly, it introduces risk at precisely the moment when consistency matters most.

A robust transfer framework includes

• Clearly defined protocols and responsibilities
• Comprehensive documentation of process parameters and equipment specifications
• Design space and DoE data
• Analytical method transfer and validation

For sterile systems, additional attention is required for aseptic operations, container-closure selection and handling, sterility assurance strategies, compatibility with single-use systems, and bulk hold times.

Common Pitfalls in Tech Transfer

Even the most well-designed technology transfer frameworks can be affected by common (and preventable) pitfalls. The most frequent failure modes in technology transfer are not technical but organizational:

• Incomplete process understanding is perhaps the most dangerous shortcoming. If the transferring team has gaps in their knowledge of how or why the process behaves as it does, those gaps become failures at the receiving site.
• Equipment mismatch is another significant risk. Even when the receiving site uses nominally similar equipment, subtle differences in design like tank geometry, impeller type, and jacket configuration can affect process performance in ways that are difficult to anticipate without thorough documentation and side-by-side comparison.
• Poor communication between sites compounds both problems. Knowledge transfer is not just documentation but is an active, cross-functional alignment between development, engineering, and manufacturing teams. When that alignment breaks down, execution gaps follow. At Agno, we address this through structured knowledge transfer processes and close collaboration across teams throughout the transfer period, not just at its conclusion.

Equipment Qualification and Facility Fit

Scaling up a process only succeeds if the manufacturing infrastructure can support it. Before any validation activity begins, equipment must be qualified, and the facility must be assessed for fit.

Key considerations include equipment scalability and cleanability (CIP/SIP compatibility), thermal and mixing capabilities of reactors and vessels, and integration of equipment across process steps to ensure seamless process flow.

Equipment qualification proceeds through three stages, each serving a distinct purpose:

• Installation Qualification (IQ): Confirms that the equipment has been installed correctly and according to regulatory specifications.
• Operational Qualification (OQ): Confirms that the equipment operates as intended across its specified operating range.
• Performance Qualification (PQ): Confirms that the equipment performs reliably under real process conditions, consistently meeting the requirements of the product being manufactured.

The timing of each stage matters. Early in development, IQ and OQ may be sufficient to support process development work. PQ becomes essential as the process matures toward commercial validation, when demonstrating reliable performance under representative conditions is a regulatory and quality requirement.

Facility requirements include ISO-class cleanrooms, environmental monitoring systems, and appropriate utilities (WFI, clean steam, and HVAC) to support sterile manufacturing. Cleaning validation is also critical to prevent cross-contamination between products.

Process Validation at Commercial Scale

Process validation is the formal demonstration that a scaled process consistently delivers a high-quality product. Following FDA guidance, validation proceeds through three stages:

• Process Design: Define process parameters, establish the control strategy, and document the scientific rationale for design space boundaries.
• Process Qualification: Execute validation batches under full GMP conditions to demonstrate that the process performs as designed.
• Continued Process Verification (CPV): Ongoing monitoring of commercial manufacturing to confirm that the process remains in a state of control.

For sterile products, validation encompasses additional elements: aseptic process simulations (media fills), filter validation, product-package integrity testing, and stability studies in final packaging. Each of these activities provides evidence that the product reaching the patient is what it was designed to be.

Risk Management in Scale-Up

Scale-up introduces risk in proportion to the complexity of the process and the interdependence of its variables. Understanding where those risks concentrate, and building mitigation strategies before they manifest, is fundamental to a successful scale-up program.

• Key Risk Areas in Scale-Up Risk Management:
  • Thermal gradients leading to API or excipient degradation
  • Inadequate mixing causing non-uniformity within batches
  • Scale-dependent changes in particle size or morphology
  • Bioburden introduction and homogeneity maintenance
  • Fill accuracy and reproducibility at commercial volumes
  • Sterility breaches during aseptic processing

• Risk Mitigation Approach: Effective risk mitigation combines structured analytical tools with practical planning:
  • FMEA-based risk assessment to systematically identify and prioritize failure modes
  • Robust design space definition through DoE to ensure process robustness across the intended operating range
  • In-process monitoring and Process Analytical Technology (PAT) for real-time visibility
  • Early sourcing and qualification of GMP-grade components and container closures
  • Dual sourcing for critical materials to reduce supply chain vulnerability
  • Redundant controls and contingency planning to manage unforeseen deviations

Effective communication across development, engineering, and manufacturing teams is critical to managing these risks. The holistic strategy to combine QbD-driven design space development, DoE-based process understanding, early sourcing and selection of GMP components, and contingency planning ensures a smooth transition from development to commercialization.

Conclusion

Scaling sterile pharmaceutical products from laboratory concept to commercial reality is one of the most technically and organizationally demanding challenges in drug development. Whether the product is a straightforward aqueous injectable or a complex advanced drug delivery system, success depends on a deeply integrated understanding of process, engineering, and product behavior.

The foundation of any successful scale-up program is a well-developed QbD framework: one that maps the process early, identifies CPPs and their interdependencies, defines a robust design space, and uses that design space as the anchor for scale-up, technology transfer, and validation. When that framework is in place, scale-up becomes a disciplined scientific exercise rather than an exercise in troubleshooting.

The elements that determine success are consistent:

• Early scalability planning integrated into process development, not as an afterthought
• Rigorous treatment of mixing and thermal dynamics as coupled, not independent, process elements
• QbD-based process development with well-defined design spaces
• Robust technology transfer supported by structured knowledge transfer and cross-functional alignment
• Proactive risk management that anticipates failure modes before they occur

At Agno, we bring together scientific expertise, engineering depth, and regulatory insight to guide clients through every stage of this process, from early feasibility through commercial manufacturing.

Ready to discuss your scale-up production?

Contact Agno’s expert team to explore how our integrated approach to drug substance manufacturing can support your development goals, including successful technology transfer in sterile dosage forms.

This article was written by Agno Pharmaceuticals based on interviews with Mithilesh Deshpande and Shreya Shah, subject-matter experts in aseptic pharmaceutical manufacturing. Their insights reflect Agno Pharmaceuticals’ hands-on experience across all phases of sterile drug development and production.